FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048716552> ?p ?o ?g. }

• W2048716552 abstract "Despite major improvements in the perioperative outcome of pancreas surgery, the prognosis of pancreatic cancer after curative resection remains poor. Adjuvant chemotherapy increases disease-free and overall survival, but this treatment cannot be offered to a significant proportion of patients due to the surgical morbidity. In contrast, almost all patients can receive (neo)adjuvant chemotherapy before surgery. This treatment is safe and effective, and has resulted in a median survival of 26.5 months in a recent phase II trial. Moreover, neoadjuvant chemotherapy improves the nutritional status of patients with pancreatic cancer. This multicenter phase III trial (NEOPAC) has been designed to explore the efficacy of neoadjuvant chemotherapy.This is a prospective randomized phase III trial. Patients with resectable cytologically proven adenocarcinoma of the pancreatic head are eligible for this study. All patients must be at least 18 years old and must provide written informed consent. An infiltration of the superior mesenteric vein > 180° or major visceral arteries are considered exclusion criteria. Eligible patients will be randomized to surgery followed by adjuvant gemcitabine (1000 mg/m(2)) for 6 months or neoadjuvant chemotherapy (gemcitabine 1000 mg/m(2), oxaliplatin 100 mg/m(2)) followed by surgery and the same adjuvant treatment. Neoadjuvant chemotherapy is given four times every two weeks. The staging as well as the restaging protocol after neoadjuvant chemotherapy include computed tomography of chest and abdomen and diagnostic laparoscopy. The primary study endpoint is progression-free survival. According to the sample size calculation, 155 patients need to be randomized to each treatment arm. Disease recurrence will be documented by scheduled computed tomography scans 9, 12, 15, 21 and thereafter every 6 months until disease progression. For quality control, circumferential resection margins are marked intraoperatively, and representative histological sections will be centrally reviewed by a dedicated pathologist.The NEOPAC study will determine the efficacy of neoadjuvant chemotherapy in pancreatic cancer for the first time and offers a unique potential for translational research. Furthermore, this trial will provide the unbiased overall survival of all patients undergoing surgery for resectable cancer of the pancreatic head.clinicalTrials.gov NCT01314027." @default.
• W2048716552 created "2016-06-24" @default.
• W2048716552 creator A5008644041 @default.
• W2048716552 creator A5019977580 @default.
• W2048716552 creator A5022762435 @default.
• W2048716552 creator A5025058942 @default.
• W2048716552 creator A5031565767 @default.
• W2048716552 creator A5035175916 @default.
• W2048716552 creator A5038131926 @default.
• W2048716552 creator A5048426715 @default.
• W2048716552 creator A5050447247 @default.
• W2048716552 creator A5061091984 @default.
• W2048716552 creator A5066597159 @default.
• W2048716552 creator A5073802838 @default.
• W2048716552 creator A5074488110 @default.
• W2048716552 creator A5081081344 @default.
• W2048716552 date "2011-08-10" @default.
• W2048716552 modified "2023-10-17" @default.
• W2048716552 title "Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)" @default.
• W2048716552 cites W1974922522 @default.
• W2048716552 cites W1990948088 @default.
• W2048716552 cites W2047318784 @default.
• W2048716552 cites W2053932797 @default.
• W2048716552 cites W2071309756 @default.
• W2048716552 cites W2090448540 @default.
• W2048716552 cites W2093115033 @default.
• W2048716552 cites W2096998881 @default.
• W2048716552 cites W2109857081 @default.
• W2048716552 cites W2115072149 @default.
• W2048716552 cites W2115812130 @default.
• W2048716552 cites W2117853299 @default.
• W2048716552 cites W2125452425 @default.
• W2048716552 cites W2125561272 @default.
• W2048716552 cites W2129197203 @default.
• W2048716552 cites W2142809913 @default.
• W2048716552 cites W2150881991 @default.
• W2048716552 cites W2151253787 @default.
• W2048716552 cites W2157590016 @default.
• W2048716552 cites W4247785462 @default.
• W2048716552 doi "https://doi.org/10.1186/1471-2407-11-346" @default.
• W2048716552 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3176241" @default.
• W2048716552 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21831266" @default.
• W2048716552 hasPublicationYear "2011" @default.
• W2048716552 type Work @default.
• W2048716552 sameAs 2048716552 @default.
• W2048716552 citedByCount "94" @default.
• W2048716552 countsByYear W20487165522012 @default.
• W2048716552 countsByYear W20487165522013 @default.
• W2048716552 countsByYear W20487165522014 @default.
• W2048716552 countsByYear W20487165522015 @default.
• W2048716552 countsByYear W20487165522016 @default.
• W2048716552 countsByYear W20487165522017 @default.
• W2048716552 countsByYear W20487165522018 @default.
• W2048716552 countsByYear W20487165522019 @default.
• W2048716552 countsByYear W20487165522020 @default.
• W2048716552 countsByYear W20487165522021 @default.
• W2048716552 countsByYear W20487165522022 @default.
• W2048716552 countsByYear W20487165522023 @default.
• W2048716552 crossrefType "journal-article" @default.
• W2048716552 hasAuthorship W2048716552A5008644041 @default.
• W2048716552 hasAuthorship W2048716552A5019977580 @default.
• W2048716552 hasAuthorship W2048716552A5022762435 @default.
• W2048716552 hasAuthorship W2048716552A5025058942 @default.
• W2048716552 hasAuthorship W2048716552A5031565767 @default.
• W2048716552 hasAuthorship W2048716552A5035175916 @default.
• W2048716552 hasAuthorship W2048716552A5038131926 @default.
• W2048716552 hasAuthorship W2048716552A5048426715 @default.
• W2048716552 hasAuthorship W2048716552A5050447247 @default.
• W2048716552 hasAuthorship W2048716552A5061091984 @default.
• W2048716552 hasAuthorship W2048716552A5066597159 @default.
• W2048716552 hasAuthorship W2048716552A5073802838 @default.
• W2048716552 hasAuthorship W2048716552A5074488110 @default.
• W2048716552 hasAuthorship W2048716552A5081081344 @default.
• W2048716552 hasBestOaLocation W20487165521 @default.
• W2048716552 hasConcept C121608353 @default.
• W2048716552 hasConcept C126322002 @default.
• W2048716552 hasConcept C141071460 @default.
• W2048716552 hasConcept C143998085 @default.
• W2048716552 hasConcept C168563851 @default.
• W2048716552 hasConcept C203092338 @default.
• W2048716552 hasConcept C2775965419 @default.
• W2048716552 hasConcept C2776694085 @default.
• W2048716552 hasConcept C2778292576 @default.
• W2048716552 hasConcept C2780140570 @default.
• W2048716552 hasConcept C2780210213 @default.
• W2048716552 hasConcept C2780258809 @default.
• W2048716552 hasConcept C2780962732 @default.
• W2048716552 hasConcept C2992435398 @default.
• W2048716552 hasConcept C526805850 @default.
• W2048716552 hasConcept C530470458 @default.
• W2048716552 hasConcept C71924100 @default.
• W2048716552 hasConceptScore W2048716552C121608353 @default.
• W2048716552 hasConceptScore W2048716552C126322002 @default.
• W2048716552 hasConceptScore W2048716552C141071460 @default.
• W2048716552 hasConceptScore W2048716552C143998085 @default.
• W2048716552 hasConceptScore W2048716552C168563851 @default.
• W2048716552 hasConceptScore W2048716552C203092338 @default.
• W2048716552 hasConceptScore W2048716552C2775965419 @default.
• W2048716552 hasConceptScore W2048716552C2776694085 @default.
• W2048716552 hasConceptScore W2048716552C2778292576 @default.

• next